Spring bank pharmaceuticals, inc. (SBPH)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

72

280

105

260

331

250

Operating expenses:
Research and development

5,303

5,200

5,228

7,275

5,567

4,563

5,656

5,555

3,977

3,923

3,221

3,404

2,527

2,769

2,723

2,936

5,589

2,760

2,101

1,545

1,133

General and administrative

2,879

2,204

2,247

2,490

2,810

2,038

2,059

2,399

2,223

2,367

1,968

1,856

1,987

1,603

1,452

1,458

1,226

1,308

1,566

1,054

1,075

Total operating expenses

8,182

7,404

7,475

9,765

8,377

6,601

7,715

7,954

6,200

6,290

5,189

5,260

4,514

4,372

4,175

4,394

6,815

4,068

3,667

2,599

2,208

Loss from operations

-8,182

-7,404

-7,475

-9,765

-8,377

-6,601

-7,715

-7,954

-6,200

-6,290

-5,189

-5,260

-4,514

-4,372

-4,175

-4,322

-6,535

-3,963

-3,407

-2,268

-1,958

Other income (expense):
Interest income

241

297

271

325

361

396

271

198

134

149

141

38

41

31

27

21

17

-

10

-

-

Interest expense

476

-

63

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-239

-151

-355

-4,885

-2,821

-780

1,336

-3,971

-1,202

-4,679

5,780

3,667

2,027

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

-

Net loss

-8,178

-7,435

-6,912

-4,555

-5,195

-5,425

-8,780

-3,785

-4,864

-1,462

-10,828

-8,889

-6,500

-2,399

-4,148

-4,301

-6,518

-3,946

-3,397

-2,263

-1,958

Unrealized gain/(loss) on marketable securities

77

3

-20

-97

-116

-

-14

-22

-

-9

-10

0

3

11

-3

4

-1

-

2

-5

-

Comprehensive loss

-8,101

-7,432

-6,932

-4,652

-5,311

-5,371

-8,794

-3,807

-4,864

-1,471

-10,838

-8,889

-6,497

-2,388

-4,151

-4,297

-6,519

-3,961

-3,395

-2,268

-1,958

Net loss per common share:
Basic

-

-

-0.42

-

-

-

-0.59

-

-

-

-0.85

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-0.42

-

-

-

-0.59

-

-

-

-0.85

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares outstanding:
Basic

-

-

16,459

-

-

-

14,841

-

-

-

12,696

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

16,459

-

-

-

14,841

-

-

-

12,696

-

-

-

-

-

-

-

-

-

-

Net loss per common share - basic and diluted

-0.49

-

-

-0.28

-0.32

-

-

-0.29

-0.37

-

-

-0.93

-0.69

-0.13

-0.53

-0.62

-1.11

-0.68

-0.59

-0.39

-0.37

Weighted-average number of shares outstanding - basic and diluted

16,523

-

-

16,443

16,436

-

-

13,179

12,991

-

-

9,517

9,416

8,465

7,759

6,923

5,877

5,802

5,796

5,796

5,336